Subunit/Conjugate and Toxoid Vaccines
Subunit, recombinant, polysaccharide, and conjugate vaccines use specific pieces of the germ—like its protein, sugar, or capsid (a casing around the germ). Because these vaccines use only specific pieces of the germ, they give a very strong immune response that’s targeted to key parts of the germ. They can also be used on almost everyone who needs them, including people with weakened immune systems and long-term health problems. Toxoid vaccines use a toxin (harmful product) made by the germ that causes a disease. They create immunity to the parts of the germ that cause disease instead of the germ itself. That means the immune response is targeted to the toxin instead of the whole germ. Like some other types of vaccines, you may need booster shots to get ongoing protection against diseases.
Toxoid vaccines are used to protect against:
- Diphtheria
- Tetanus
Related Conference of Subunit/Conjugate and Toxoid Vaccines
9th International Conference on Vaccines, Immunology and Clinical Trials
7th International conference on Vaccines, Vaccination and Immunization
Subunit/Conjugate and Toxoid Vaccines Conference Speakers
Recommended Sessions
- Benefits of getting a COVID-19 vaccine
- Biomarkers and Case Reports
- Coronavirus (Covid 19) and Next-Generation Vaccines
- Different types of COVID-19 vaccines
- Emerging and Infectious Diseases
- HIV Vaccines
- Human Vaccines-Infectious and Non-Infectious
- Immunization and Bioprocessing
- Immunization Safety and Vaccination Schedule
- Influenza and Respiratory Vaccines
- Live Attenuated and Inactivated Vaccines
- Side-effects of Antibiotics & Vaccines
- Subunit/Conjugate and Toxoid Vaccines
- Vaccine Hesitancy and Health Literacy
- Vaccine Safety and Efficacy
- Vaccines for Infectious and Non-infectious Diseases
- Vaccines Manufacturing Technologies
- Veterinary Vaccines and Animal Health
- Viral Vaccines and Bacterial Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Bioinformatics and AI in Vaccine Design - Vaccine Immunology 2026 (France)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Challenges in Vaccine Accessibility and Equity - Vaccine Immunology 2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Clinical Vaccinology and Immunotherapy - Vaccine Immunology 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- Emerging Infectious Diseases - Vaccine Immunology 2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Future Directions in Vaccine Research - Vaccine Immunology 2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Global Vaccination Strategies - Vaccine Immunology 2026 (France)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Human Microbiome and Vaccines - Vaccine Immunology 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (France)
- Immunology and Immune System Innovations - Vaccine Immunology 2026 (France)
- Immunology of Infectious Diseases - Vaccine Immunology 2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Immunotherapy and Vaccines for Non-Infectious Diseases - Vaccine Immunology 2026 (France)
- Immunotherapy in Cancer Treatment - Vaccine Immunology 2026 (France)
- Industry and Technology Innovations - Vaccine Immunology 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Maternal, Neonatal, and Geriatric Immunization - Vaccine Immunology 2026 (France)
- Microbiome-Targeted Vaccines - Vaccine Immunology 2026 (France)
- Nanotechnology and Advanced Delivery Systems - Vaccine Immunology 2026 (France)
- Nanotechnology in Vaccine Delivery - Vaccine Immunology 2026 (France)
- Next-Generation Vaccine Platforms - Vaccine Immunology 2026 (France)
- Novel Vaccine Platforms: mRNA, DNA, and Viral Vectors - Vaccine Immunology 2026 (France)
- One Health Approach to Vaccine Development - Vaccine Immunology 2026 (France)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Pandemic Preparedness and Response - Vaccine Immunology 2026 (France)
- Public Health and Global Immunization - Vaccine Immunology 2026 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The Economics of Vaccination - Vaccine Immunology 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Trust - Vaccine Immunology 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Production and Global Supply Chains - Vaccine Immunology 2026 (France)
- Vaccine Research and Development - Vaccine Immunology 2026 (France)
- Vaccine Safety and Adverse Event Monitoring - Vaccine Immunology 2026 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety, Pharmacovigilance, and Adverse Event Monitoring - Vaccine Immunology 2026 (France)
- Vaccine-Induced Immunity and Duration of Protection - Vaccine Immunology 2026 (France)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)

